SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback